Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group - PubMed (original) (raw)
Multicenter Study
. 2013 Nov 1;119(21):3887-94.
doi: 10.1002/cncr.28239. Epub 2013 Aug 26.
Affiliations
- PMID: 23983061
- PMCID: PMC4362793
- DOI: 10.1002/cncr.28239
Multicenter Study
Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group
Eric J Gratias et al. Cancer. 2013.
Abstract
Background: Wilms tumor is the most common childhood renal tumor. Although the majority of patients with favorable histology Wilms tumor (FHWT) have good outcomes, some patients still experience disease recurrence and death from disease. The goal of the current study was to determine whether tumor-specific chromosome 1q gain is associated with event-free survival (EFS) and overall survival (OS) in patients with FHWT.
Methods: Unilateral FHWT samples were obtained from patients enrolled on National Wilms Tumor Study-4 and Pediatric Oncology Group Wilms Biology Study (POG 9046). 1q gain, 1p loss, and 16q loss were determined using multiplex ligation-dependent probe amplification.
Results: The 8-year EFS rate was 87% (95% confidence interval [95% CI], 82%-91%) for the entire cohort of 212 patients. Tumors from 58 of 212 patients (27%) displayed 1q gain. A strong relationship between 1q gain and 1p/16q loss was observed. The 8-year EFS rate was 76% (95% CI, 63%-85%) for patients with 1q gain and 93% (95% CI, 87%-96%) for those lacking 1q gain (P = .0024). The 8-year OS rate was 89% (95% CI, 78%-95%) for those with 1q gain and 98% (95% CI, 94%-99%) for those lacking 1q gain (P = .0075). Gain of 1q was not found to correlate with disease stage (P = .16). After stratification for stage of disease, 1q gain was associated with a significantly increased risk of disease recurrence (risk ratio estimate: 2.72; P = .0089).
Conclusions: Gain of 1q may provide a valuable prognostic marker with which to stratify therapy for patients with FHWT. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies.
Keywords: Wilms tumor; chromosome 1; kidney; pediatrics; prognosis.
© 2013 American Cancer Society.
Figures
Figure 1
Event-free survival stratified for 1q gain
Figure 2
Overall survival stratified for 1q gain
Figure 3
Mechanisms responsible for 1q gain A. Translocations involving chromosome 1 (the most common also involves chromosome 16). All tumors with t(1;16) examined thus far show loss of the der(1) and retention of the der(16). This results in loss of copy number and LOH for 1p and 16q. Tumors also variably show duplication of the normal chromosomes 1 and/or 16. While this increases the copy number for these chromosomal arms, because there are two exact copies, LOH is seen. B. Isochromosome 1q results from the development of a derivative chromosome 1 that contains two mirror-image copies of 1q. The normal chromosome 1 remains, resulting in 1q gain and 1p LOH. Again, the normal chromosome 1 is often duplicated, resulting in copy neutral LOH for 1p.
Comment in
- 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk stratification in the SIOP2001/GPOH trial.
Vokuhl C, Vogelgesang W, Leuschner I, Furtwängler R, Graf N, Gessler M, Dörner E, Pietsch T. Vokuhl C, et al. Genes Chromosomes Cancer. 2014 Nov;53(11):960-2. doi: 10.1002/gcc.22203. Epub 2014 Jul 18. Genes Chromosomes Cancer. 2014. PMID: 25044466 No abstract available.
Similar articles
- Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ. Gratias EJ, et al. J Clin Oncol. 2016 Sep 10;34(26):3189-94. doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11. J Clin Oncol. 2016. PMID: 27400937 Free PMC article. - Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Fernandez CV, et al. J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6. J Clin Oncol. 2018. PMID: 29211618 Free PMC article. - Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O'Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K. Chagtai T, et al. J Clin Oncol. 2016 Sep 10;34(26):3195-203. doi: 10.1200/JCO.2015.66.0001. Epub 2016 Jul 18. J Clin Oncol. 2016. PMID: 27432915 Free PMC article. Clinical Trial. - Risk stratification for wilms tumor: current approach and future directions.
Dome JS, Perlman EJ, Graf N. Dome JS, et al. Am Soc Clin Oncol Educ Book. 2014:215-23. doi: 10.14694/EdBook_AM.2014.34.215. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857079 Review. - New approaches to risk stratification for Wilms tumor.
Nelson MV, van den Heuvel-Eibrink MM, Graf N, Dome JS. Nelson MV, et al. Curr Opin Pediatr. 2021 Feb 1;33(1):40-48. doi: 10.1097/MOP.0000000000000988. Epub 2020 Dec 29. Curr Opin Pediatr. 2021. PMID: 33394739 Free PMC article. Review.
Cited by
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.
Janssen FW, Lak NSM, Janda CY, Kester LA, Meister MT, Merks JHM, van den Heuvel-Eibrink MM, van Noesel MM, Zsiros J, Tytgat GAM, Looijenga LHJ. Janssen FW, et al. NPJ Precis Oncol. 2024 Aug 3;8(1):172. doi: 10.1038/s41698-024-00657-z. NPJ Precis Oncol. 2024. PMID: 39097671 Free PMC article. Review. - Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.
Karam S, Gebreil A, Alksas A, Balaha HM, Khalil A, Ghazal M, Contractor S, El-Baz A. Karam S, et al. Biomedicines. 2024 Jun 30;12(7):1455. doi: 10.3390/biomedicines12071455. Biomedicines. 2024. PMID: 39062028 Free PMC article. Review. - Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis.
Song YH, Li WL, Yang Z, Gao Y, Feng ZP. Song YH, et al. World J Gastrointest Oncol. 2024 May 15;16(5):2159-2167. doi: 10.4251/wjgo.v16.i5.2159. World J Gastrointest Oncol. 2024. PMID: 38764827 Free PMC article. - Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
Benedetti DJ, Varela CR, Renfro LA, Tornwall B, Dix DB, Ehrlich PF, Glick RD, Kalapurakal J, Perlman E, Gratias E, Seibel NL, Geller JI, Khanna G, Malogolowkin M, Grundy P, Fernandez CV, Dome JS, Mullen EA. Benedetti DJ, et al. Cancer. 2024 Mar 15;130(6):947-961. doi: 10.1002/cncr.35099. Epub 2023 Nov 7. Cancer. 2024. PMID: 37933882 Clinical Trial. - Hallmark discoveries in the biology of Wilms tumour.
Perotti D, Williams RD, Wegert J, Brzezinski J, Maschietto M, Ciceri S, Gisselsson D, Gadd S, Walz AL, Furtwaengler R, Drost J, Al-Saadi R, Evageliou N, Gooskens SL, Hong AL, Murphy AJ, Ortiz MV, O'Sullivan MJ, Mullen EA, van den Heuvel-Eibrink MM, Fernandez CV, Graf N, Grundy PE, Geller JI, Dome JS, Perlman EJ, Gessler M, Huff V, Pritchard-Jones K. Perotti D, et al. Nat Rev Urol. 2024 Mar;21(3):158-180. doi: 10.1038/s41585-023-00824-0. Epub 2023 Oct 17. Nat Rev Urol. 2024. PMID: 37848532 Review.
References
- Bernstein L, Linet M, Smith MA, Olshan AF. Renal Tumors. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD: 1999. pp. 79–90.
- Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumor. Cancer. 1978;41(5):1937–1948. - PubMed
- Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol. 1996;20:909–920. - PubMed
- Gratias EJ, Dome JS. Current and Emerging Chemotherapy Treatment Strategies for Wilms Tumor in North America. Pediatr Drugs. 2008;10(2):115–124. - PubMed
- D’Angio GJ, Evans AE, Breslow NE, et al. The Treatment of Wilms’ Tumor, Results of the National Wilms Tumor Study. Cancer. 1976;38(2):633–646. - PubMed
Publication types
MeSH terms
Grants and funding
- CA-98543/CA/NCI NIH HHS/United States
- R21 CA155556/CA/NCI NIH HHS/United States
- CA-54498/CA/NCI NIH HHS/United States
- U10 CA098413/CA/NCI NIH HHS/United States
- U10 CA098543/CA/NCI NIH HHS/United States
- CA155556A/CA/NCI NIH HHS/United States
- R01 CA054498/CA/NCI NIH HHS/United States
- CA-42326/CA/NCI NIH HHS/United States
- CA-98413/CA/NCI NIH HHS/United States
- U10 CA042326/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical